GlassScriptPhysician profile
Shaker R Dakhil
NPI 1417918079
$579,239.41
in general payments reported to CMS, 2019-2025
100 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $126K · 2021: $113K · 2022: $66K · 2023: $86K · 2024: $43K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $52K · Charitable Contribution: $30K · Travel and Lodging: $20K · Food and Beverage: $13K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,032.00 |
| Consulting Fee | $52,403.25 |
| Charitable Contribution | $30,000.00 |
| Travel and Lodging | $20,132.35 |
| Food and Beverage | $13,355.45 |
| Education | $211.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $125,024.16 | 2019-2025 | Datroway, Enhertu, Vanflyta |
| US Oncology Corporate, INC. | $120,069.93 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $73,134.72 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $34,631.75 | 2019-2025 | |
| Mckesson Specialty Care Distribution, LLC | $30,000.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29,061.45 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Celgene Corporation | $13,802.09 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $13,647.87 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Seagen INC. | $13,576.38 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Pfizer INC. | $13,471.09 | 2019-2025 | |
| Astellas Pharma US INC | $10,745.61 | 2019-2024 | Xospata, Padcev, Xtandi |
| Abbvie INC. | $10,450.22 | 2019-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $9,810.57 | 2019-2025 | Scemblix |
| Kite Pharma, INC. | $6,827.28 | 2020-2025 | Tecartus, Yescarta |
| Gilead Sciences, INC. | $6,634.47 | 2019-2025 | Trodelvy |
Show all 99 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $5,092.44 | 2019 | |
| Amag Pharmaceuticals, INC. | $4,995.36 | 2019-2021 | |
| Mylan Institutional INC. | $4,155.43 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,094.94 | 2019-2024 | |
| Glaxosmithkline, LLC. | $3,681.18 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Fresenius Kabi USA, LLC | $3,150.00 | 2021 | |
| Amgen INC. | $2,997.35 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $2,804.73 | 2019-2025 | Iclusig, Ninlaro |
| Taiho Oncology, INC. | $2,564.65 | 2019-2025 | |
| Epizyme, INC. | $2,294.46 | 2020-2022 | |
| Incyte Corporation | $2,044.25 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Jazz Pharmaceuticals INC. | $1,973.12 | 2019-2025 | |
| Beigene, LTD. | $1,950.00 | 2021 | |
| Morphosys, US INC. | $1,849.45 | 2021-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $1,784.74 | 2021-2025 | Fotivda |
| Verastem, INC. | $1,492.10 | 2019-2020 | |
| Coherus Oncology, INC. | $1,424.69 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $1,379.55 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Geron Corporation | $1,225.15 | 2025 | Rytelo |
| Genentech USA, INC. | $1,188.20 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Dova Pharmaceuticals | $1,080.51 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $1,058.60 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $1,023.72 | 2020-2025 | Xpovio |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2021 | |
| Array Biopharma INC | $944.28 | 2019-2025 | Xalkori, Mektovi, Braftovi |
| Halozyme INC | $900.00 | 2019 | |
| Eagle Pharmaceuticals, INC. | $850.00 | 2022 | |
| Genzyme Corporation | $761.65 | 2019-2025 | |
| Tersera Therapeutics LLC | $510.19 | 2019-2025 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $465.86 | 2019-2025 | Libtayo, Lynozyfic |
| Puma Biotechnology, INC. | $439.78 | 2019-2022 | |
| Emd Serono, INC. | $422.58 | 2019-2025 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $351.90 | 2019-2023 | Imbruvica |
| Exelixis INC. | $338.67 | 2019-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $312.09 | 2019-2025 | Onivyde, Tazverik |
| Clovis Oncology, INC. | $249.27 | 2019-2020 | |
| Blueprint Medicines Corporation | $233.68 | 2020-2024 | Ayvakit |
| Servier Pharmaceuticals LLC | $201.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $181.43 | 2019-2024 | Yonsa, Odomzo |
| Tesaro, INC. | $179.93 | 2019 | |
| Sobi, INC | $174.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.31 | 2019-2025 | Gilotrif |
| Blue Earth Diagnostics | $159.08 | 2019-2025 | Posluma |
| Stemline Therapeutics INC. | $157.97 | 2023-2025 | Orserdu, Elzonris |
| Heron Therapeutics, INC. | $156.43 | 2019-2022 | |
| Beigene USA, INC. | $153.29 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $147.68 | 2023-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $146.89 | 2022-2025 | Clonoseq |
| Dendreon Pharmaceuticals LLC | $141.77 | 2020-2025 | Provenge |
| Genmab U.S., INC. | $131.18 | 2023-2025 | Epkinly, Tivdak |
| Alexion Pharmaceuticals, INC. | $121.69 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $100.94 | 2019-2024 | Verzenio |
| Pharmacosmos Therapeutics INC. | $95.86 | 2023-2025 | Monoferric |
| Foundation Medicine, INC. | $90.30 | 2021-2022 | |
| G1 Therapeutics, INC. | $70.30 | 2022-2023 | Cosela |
| Immunocore Limited | $69.38 | 2025 | Kimmtrak |
| Cti Biopharma Corp. | $69.32 | 2022-2023 | Vonjo |
| Mirati Therapeutics, INC. | $68.39 | 2023-2024 | Krazati |
| Springworks Therapeutics, INC. | $67.71 | 2024-2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $63.93 | 2023-2025 | Qinlock |
| Pharmaessentia USA Corporation | $63.07 | 2022-2023 | Besremi |
| Celltrion USA INC. | $62.37 | 2024 | Vegzelma |
| Amneal Pharmaceuticals LLC | $61.60 | 2024-2025 | Alymsys, Pemrydi Rtu, Neupogen |
| Agios Pharmaceuticals, INC. | $56.53 | 2020-2025 | Pyrukynd |
| Avyxa Pharma, LLC | $54.16 | 2025 | |
| Acrotech Biopharma INC. | $53.29 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $52.48 | 2021-2025 | Myrisk |
| Kyowa Kirin, INC. | $51.64 | 2019-2021 | |
| Caris Mpi, INC. | $48.54 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $46.07 | 2024-2025 | Rolvedon |
| Iovance Biotherapeutics, INC. | $43.60 | 2024-2025 | Amtagvi |
| Octapharma USA, INC. | $43.31 | 2023-2025 | Octagam Immune Globulin (Human) |
| Legend Biotech USA INC. | $40.90 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $40.10 | 2024 | Empaveli |
| Aurobindo Pharma USA, INC. | $35.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.87 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $27.16 | 2024-2025 | Enjaymo, Sylvant |
| Shield Therapeutics INC | $21.39 | 2025 | |
| Secura Bio, INC. | $20.50 | 2025 | Copiktra |
| Tg Therapeutics, INC. | $19.80 | 2022 | |
| Syndax Pharmaceuticals, INC. | $18.36 | 2025 | |
| Medtronic, INC. | $18.13 | 2023 | Synchromedii |
| Tolmar, INC. | $17.00 | 2025 | Eligard, Rubraca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$80,798.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaker Dakhil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.